Using a dosing app for insulin management
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial studies a smartphone system that helps people with diabetes decide how much insulin to take. It is for people who use insulin injections or are starting basal insulin, and it uses a continuous glucose monitor to guide dosing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 1 or type 2 diabetes for at least 6 months.
- You are between 6 and 75 years old.
- Your HbA1c is 11% or lower.
- You use insulin injections (either multiple daily doses or a once-daily basal insulin).
- You are willing to wear a FreeStyle Libre continuous glucose monitor and use a compatible smartphone.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a system that measures blood sugar and automatically adjusts insulin delivery. It is for adults with type 1 diabetes who use insulin injections or a pump.
This study tests a new automated insulin delivery system to help people with type 1 diabetes better manage their blood sugar. It aims to see if the system improves glucose control safely.
This trial tests a smartphone app that helps people with type 1 diabetes predict their blood sugar and decide how much insulin to take. It may be a good fit if you already use multiple daily insulin injections and a continuous glucose monitor.
This trial tests the EkiYou smartphone app to help calculate your mealtime insulin dose. You need to have diabetes, use both a long-acting and a short-acting insulin pen, and be comfortable with a CGM and a smartphone.
This study tests an app-based diabetes education program for people with type 1 diabetes. It aims to see if the app can help you manage your blood sugar levels better using insulin pens and a continuous glucose monitor.
This trial tests MODI, a smartphone app that helps automatically adjust your insulin doses based on blood sugar readings from a continuous glucose monitor. The study checks if this system is safe and helps people with type 1 or type 2 diabetes manage their blood sugar better.
Hear when a new Type 1 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.